Piper Sandler raised the firm’s price target on Hinge Health (HNGE) to $95 from $60 and keeps an Overweight rating on the shares. The firm notes the company reported extremely strong Q1 results where revenue exceeded the midpoint of guidance by $10.3M and was up 47.2% year-over-year. Hinge launched Migraine Care and took the first definitive step outside of MSK this quarter, Piper adds, pointing out that the company is executing on product innovation, engagement, go to market and margin. The firm would be a buyer of the momentum into Hinge’s first Investor Day in June.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health Earnings Call Signals Profitable Growth
- Hinge Health Lifts 2026 Outlook After Record Quarter
- Hinge Health Buy Rating Reiterated on Growth Momentum and Migraine Expansion, Price Target Maintained at $72
- Analyst Reiterates Buy on Hinge Health, Citing Near‑Term Outperformance Potential and Long‑Term Growth from New Migraine Care Program
- Hinge Health launching migraine treatment program, WSJ reports